CO6251236A2 - Composiciones terapeuticas que comprenden acido 6-(3-cloro-2-fluorobencil)-1´-[(25)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxilico - Google Patents
Composiciones terapeuticas que comprenden acido 6-(3-cloro-2-fluorobencil)-1´-[(25)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxilicoInfo
- Publication number
- CO6251236A2 CO6251236A2 CO09146050A CO09146050A CO6251236A2 CO 6251236 A2 CO6251236 A2 CO 6251236A2 CO 09146050 A CO09146050 A CO 09146050A CO 09146050 A CO09146050 A CO 09146050A CO 6251236 A2 CO6251236 A2 CO 6251236A2
- Authority
- CO
- Colombia
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- composition
- dihydroquinolin
- oxo
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 9
- 239000002253 acid Substances 0.000 title abstract 5
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 9
- 150000001875 compounds Chemical class 0.000 abstract 4
- -1 3-chloro-2-fluorobenzyl Chemical group 0.000 abstract 2
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 abstract 2
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 abstract 2
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 abstract 2
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 abstract 2
- 229960004525 lopinavir Drugs 0.000 abstract 2
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 abstract 2
- 229960000311 ritonavir Drugs 0.000 abstract 2
- VLRGXXKFHVJQOL-UHFFFAOYSA-N 3-chloropentane-2,4-dione Chemical compound CC(=O)C(Cl)C(C)=O VLRGXXKFHVJQOL-UHFFFAOYSA-N 0.000 abstract 1
- 102000018832 Cytochromes Human genes 0.000 abstract 1
- 108010052832 Cytochromes Proteins 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- JUZYLCPPVHEVSV-LJQANCHMSA-N elvitegravir Chemical compound COC1=CC=2N([C@H](CO)C(C)C)C=C(C(O)=O)C(=O)C=2C=C1CC1=CC=CC(Cl)=C1F JUZYLCPPVHEVSV-LJQANCHMSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000011347 resin Substances 0.000 abstract 1
- 229920005989 resin Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94732507P | 2007-06-29 | 2007-06-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6251236A2 true CO6251236A2 (es) | 2011-02-21 |
Family
ID=39817166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO09146050A CO6251236A2 (es) | 2007-06-29 | 2009-12-21 | Composiciones terapeuticas que comprenden acido 6-(3-cloro-2-fluorobencil)-1´-[(25)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxilico |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US20090093482A1 (enExample) |
| EP (1) | EP2167089A1 (enExample) |
| JP (3) | JP5547067B2 (enExample) |
| KR (1) | KR20100028656A (enExample) |
| CN (2) | CN101743004A (enExample) |
| AP (1) | AP2490A (enExample) |
| AR (1) | AR067184A1 (enExample) |
| AU (1) | AU2008270634B2 (enExample) |
| BR (1) | BRPI0813955A2 (enExample) |
| CA (1) | CA2691736A1 (enExample) |
| CO (1) | CO6251236A2 (enExample) |
| EA (1) | EA200971096A1 (enExample) |
| EC (1) | ECSP109889A (enExample) |
| IL (1) | IL202745A0 (enExample) |
| MX (1) | MX2009013828A (enExample) |
| NZ (1) | NZ582089A (enExample) |
| SG (1) | SG182228A1 (enExample) |
| TW (1) | TW200916103A (enExample) |
| UA (1) | UA103881C2 (enExample) |
| WO (1) | WO2009006203A1 (enExample) |
| ZA (1) | ZA201000468B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0620865A2 (pt) * | 2005-12-30 | 2011-11-29 | Gilead Sciences Inc | métodos para melhorar a farmacocinética de inibidores das integrases do hiv |
| SI2049506T2 (sl) | 2006-07-07 | 2024-07-31 | Gilead Sciences, Inc. | Modulatorji farmakokinetičnih lastnosti terapevtikov |
| BRPI0716752A2 (pt) | 2006-09-12 | 2013-09-17 | Gilead Sciences Inc | processo e intermediÁrios para preparo de inibidores de intergrase |
| EP4403221A3 (en) * | 2007-02-23 | 2024-10-09 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
| NZ582086A (en) * | 2007-06-29 | 2012-07-27 | Gilead Sciences Inc | Therapeutic compositions and the use thereof |
| AR068403A1 (es) | 2007-09-11 | 2009-11-18 | Gilead Sciences Inc | Proceso e intermediarios para la preparacion de inhibidores de integrasa |
| CN103479584A (zh) | 2008-05-02 | 2014-01-01 | 吉里德科学公司 | 固体载体颗粒在改善药物制剂加工性中的应用 |
| JP6158702B2 (ja) * | 2010-04-09 | 2017-07-05 | ブリストル−マイヤーズ・スクイブ・ホールディングス・アイルランドＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｈｏｌｄｉｎｇｓ Ｉｒｅｌａｎｄ | ｐＨの影響を改善したアタザナビル硫酸塩製剤 |
| US20130274254A1 (en) * | 2010-12-21 | 2013-10-17 | Gilead Sciences, Inc. | Inhibitors of cytochrome p450 (cyp3a4) |
| CA3131037A1 (en) | 2011-11-30 | 2013-06-06 | Emory University | Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections |
| JP2015508822A (ja) * | 2012-03-01 | 2015-03-23 | ギリアード サイエンシーズ， インコーポレイテッド | 噴霧乾燥製剤 |
| NZ630199A (en) | 2012-08-03 | 2016-12-23 | Gilead Sciences Inc | Process and intermediates for preparing integrase inhibitors |
| CA2893843C (en) | 2012-12-21 | 2018-09-04 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
| NO2865735T3 (enExample) | 2013-07-12 | 2018-07-21 | ||
| DK3019503T3 (da) | 2013-07-12 | 2017-11-20 | Gilead Sciences Inc | Polycykliske-carbamoylpyridon-forbindelser og anvendelse deraf til behandling af hiv-infektioner |
| NO2717902T3 (enExample) | 2014-06-20 | 2018-06-23 | ||
| TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
| TWI677489B (zh) | 2014-06-20 | 2019-11-21 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
| TWI738321B (zh) | 2014-12-23 | 2021-09-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
| IL296496B2 (en) | 2014-12-26 | 2024-10-01 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| TR201905009T4 (tr) | 2015-04-02 | 2019-05-21 | Gilead Sciences Inc | Polisiklik-karbamoilpiridon bileşikleri ve bunların farmasötik kullanımları. |
| KR102626210B1 (ko) | 2017-12-07 | 2024-01-18 | 에모리 유니버시티 | N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5539122A (en) * | 1989-05-23 | 1996-07-23 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| GB8927913D0 (en) * | 1989-12-11 | 1990-02-14 | Hoffmann La Roche | Amino acid derivatives |
| US5413999A (en) * | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
| US5484926A (en) * | 1993-10-07 | 1996-01-16 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
| US5914332A (en) * | 1995-12-13 | 1999-06-22 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| US5849911A (en) * | 1996-04-22 | 1998-12-15 | Novartis Finance Corporation | Antivirally active heterocyclic azahexane derivatives |
| US6087383A (en) * | 1998-01-20 | 2000-07-11 | Bristol-Myers Squibb Company | Bisulfate salt of HIV protease inhibitor |
| WO2004046115A1 (ja) * | 2002-11-20 | 2004-06-03 | Japan Tobacco Inc. | ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用 |
| US20060111933A1 (en) * | 2003-10-09 | 2006-05-25 | Steven Wheeler | Adaptive medical decision support system |
| MY134672A (en) * | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
| EP2229945A1 (en) * | 2004-05-21 | 2010-09-22 | Japan Tobacco, Inc. | Combinations comprising a 4-isoquinolone derivative and anti-HIV agents |
| US20060058286A1 (en) * | 2004-09-16 | 2006-03-16 | Mark Krystal | Methods of treating HIV infection |
| BRPI0620865A2 (pt) * | 2005-12-30 | 2011-11-29 | Gilead Sciences Inc | métodos para melhorar a farmacocinética de inibidores das integrases do hiv |
| US20090233964A1 (en) * | 2005-12-30 | 2009-09-17 | Gilead Sciences, Inc. | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
| WO2007092802A1 (en) * | 2006-02-09 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Method for treating hiv infection through co-administration of tipranavir and gs 9137 |
| SI2049506T2 (sl) * | 2006-07-07 | 2024-07-31 | Gilead Sciences, Inc. | Modulatorji farmakokinetičnih lastnosti terapevtikov |
| BRPI0716752A2 (pt) * | 2006-09-12 | 2013-09-17 | Gilead Sciences Inc | processo e intermediÁrios para preparo de inibidores de intergrase |
| NZ582086A (en) * | 2007-06-29 | 2012-07-27 | Gilead Sciences Inc | Therapeutic compositions and the use thereof |
| AR068403A1 (es) * | 2007-09-11 | 2009-11-18 | Gilead Sciences Inc | Proceso e intermediarios para la preparacion de inhibidores de integrasa |
| CN103479584A (zh) * | 2008-05-02 | 2014-01-01 | 吉里德科学公司 | 固体载体颗粒在改善药物制剂加工性中的应用 |
| US20110000941A1 (en) * | 2009-07-06 | 2011-01-06 | Volk J Patrick | Apparatus and System for Carrying a Digital Media Player |
-
2008
- 2008-06-26 BR BRPI0813955A patent/BRPI0813955A2/pt not_active IP Right Cessation
- 2008-06-26 TW TW097123981A patent/TW200916103A/zh unknown
- 2008-06-26 CA CA002691736A patent/CA2691736A1/en not_active Abandoned
- 2008-06-26 SG SG2012046926A patent/SG182228A1/en unknown
- 2008-06-26 US US12/147,220 patent/US20090093482A1/en not_active Abandoned
- 2008-06-26 AP AP2009005083A patent/AP2490A/xx active
- 2008-06-26 CN CN200880022821A patent/CN101743004A/zh active Pending
- 2008-06-26 AU AU2008270634A patent/AU2008270634B2/en not_active Ceased
- 2008-06-26 MX MX2009013828A patent/MX2009013828A/es not_active Application Discontinuation
- 2008-06-26 WO PCT/US2008/068351 patent/WO2009006203A1/en not_active Ceased
- 2008-06-26 EA EA200971096A patent/EA200971096A1/ru unknown
- 2008-06-26 KR KR1020107001984A patent/KR20100028656A/ko not_active Ceased
- 2008-06-26 US US12/666,995 patent/US20110009411A1/en not_active Abandoned
- 2008-06-26 UA UAA200913904A patent/UA103881C2/ru unknown
- 2008-06-26 EP EP20080781024 patent/EP2167089A1/en not_active Withdrawn
- 2008-06-26 JP JP2010515115A patent/JP5547067B2/ja not_active Expired - Fee Related
- 2008-06-26 CN CN2013101948825A patent/CN103356622A/zh active Pending
- 2008-06-26 AR ARP080102760A patent/AR067184A1/es not_active Application Discontinuation
- 2008-06-26 NZ NZ582089A patent/NZ582089A/xx not_active IP Right Cessation
-
2009
- 2009-12-15 IL IL202745A patent/IL202745A0/en unknown
- 2009-12-21 CO CO09146050A patent/CO6251236A2/es not_active Application Discontinuation
-
2010
- 2010-01-21 ZA ZA2010/00468A patent/ZA201000468B/en unknown
- 2010-01-21 EC EC2010009889A patent/ECSP109889A/es unknown
-
2013
- 2013-07-08 JP JP2013142320A patent/JP5769762B2/ja not_active Expired - Fee Related
-
2014
- 2014-05-19 US US14/281,790 patent/US20140343062A1/en not_active Abandoned
-
2015
- 2015-05-07 JP JP2015094705A patent/JP2015143277A/ja not_active Withdrawn
-
2016
- 2016-10-19 US US15/298,070 patent/US20170136000A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015143277A (ja) | 2015-08-06 |
| JP2013199494A (ja) | 2013-10-03 |
| JP2010532373A (ja) | 2010-10-07 |
| WO2009006203A1 (en) | 2009-01-08 |
| EA200971096A1 (ru) | 2010-08-30 |
| AU2008270634B2 (en) | 2014-01-16 |
| AP2009005083A0 (en) | 2009-12-31 |
| SG182228A1 (en) | 2012-07-30 |
| KR20100028656A (ko) | 2010-03-12 |
| CN101743004A (zh) | 2010-06-16 |
| IL202745A0 (en) | 2010-06-30 |
| AP2490A (en) | 2012-10-04 |
| ZA201000468B (en) | 2011-06-29 |
| CA2691736A1 (en) | 2009-01-08 |
| CN103356622A (zh) | 2013-10-23 |
| ECSP109889A (es) | 2010-03-31 |
| US20170136000A1 (en) | 2017-05-18 |
| JP5547067B2 (ja) | 2014-07-09 |
| US20140343062A1 (en) | 2014-11-20 |
| AR067184A1 (es) | 2009-09-30 |
| US20090093482A1 (en) | 2009-04-09 |
| EP2167089A1 (en) | 2010-03-31 |
| BRPI0813955A2 (pt) | 2017-05-09 |
| US20110009411A1 (en) | 2011-01-13 |
| NZ582089A (en) | 2013-01-25 |
| MX2009013828A (es) | 2010-03-10 |
| AU2008270634A1 (en) | 2009-01-08 |
| JP5769762B2 (ja) | 2015-08-26 |
| UA103881C2 (ru) | 2013-12-10 |
| TW200916103A (en) | 2009-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2011002830A1 (es) | Compuestos derivados de haloalquil heteroaril benzamidas; composicion farmaceutica uso de la composicion en el tratamiento de una infeccion viral, tal como el virus de la hepatitis b y c. | |
| CL2007003299A1 (es) | Compuestos derivados de macrociclos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c. | |
| CL2007003352A1 (es) | Compuestos derivados de heteromonociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades circulatorias, enfermedades metabolicas y/o enfermedades del sistema nervioso cen | |
| AR067184A1 (es) | Uso de 6-(3-cloro-2-fluorbencil)-1-[(2s)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxilico. composicion farmaceutica | |
| CL2007001992A1 (es) | Compuestos derivados de pirimidilciclopentanos; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodege | |
| CL2008001297A1 (es) | N-[(1s)-1-(5-fluoropirim idin-2-i1 )etil]-3-(5-isopropoxi-1 h-pirazol-3-il )-3h-imidazo[4,5-b]piridin-5amina o una sal farmacéuticamente aceptabie del mismo; composición farmacéutica que lo comprende; y su uso en el tratamiento del cáncer. | |
| AR074471A1 (es) | Compuesto 5(5-(2-(3-aminopropoxi) - 6 - metoxifenil) -1h- pirazol-3- ilamino ) pirazin -2-carbonitrilo , composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para inhibir chk1 y para tratar cancer | |
| CL2013002417A1 (es) | Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas. | |
| CL2007002234A1 (es) | Compuestos derivados de heterociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades proliferativas. | |
| CL2007003540A1 (es) | Compuestos derivados de macrociclos, inhibidores de la proteasa serina de hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c. | |
| CL2009001980A1 (es) | Combinacion farmaceutica que comprende un derivado de quinolina y uno o mas de otros agentes antimicobacterianos; composicion farmaceutica que la comprende; y uso para el tratamiento de una infeccion por una cepa de mycobacterium resistente a farmacos (divisional de la solicitud 1290-05). | |
| AR062980A1 (es) | Composiciones farmaceuticas de compuestos de pirimidil-amino-benzamida | |
| MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
| BR112012033077B8 (pt) | Composição farmacêutica para administração intravenosa, uso de uma composição farmacêutica, e, kit | |
| ECSP10010413A (es) | Inhibidores macrociclicos de serina proteasa | |
| CL2008001005A1 (es) | Compuestos derivados de azufre, inhibidores de la serina proteasa ns3 del virus de la hepatitis c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos asociados a la proteasa de hcv. | |
| ECSP109897A (es) | Composiciones terapeuticas y usos de las mismas | |
| CL2008002049A1 (es) | Compuestos derivados de aminoindol macrociclicos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c. | |
| GT200600163A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
| CL2012001176A1 (es) | Compuestos derivados de bencimidazol-imidazol, inhibidores del virus de la hepatitis c (hcv); composición farmacéutica que los comprende; combinación farmacéutica; uso en la prevención o tratamiento de infección de hcv. | |
| CR20140540A (es) | Nueva forma de dosificación y formulación de abediterol | |
| AR076388A1 (es) | Procedimientos para mejorar la farmocinetica | |
| MX2020010697A (es) | Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil. | |
| AR077139A1 (es) | Composiciones farmaceuticas utiles para tratar el vch | |
| ECSP15051434A (es) | Composición farmacéutica de dosis baja |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |